Loading company…
Microbiotica, based in Cambridge, UK, develops live biotherapeutic medicines for immuno-oncology and inflammatory bowel disease.
Founded in 2016 and headquartered in Cambridge, UK, Microbiotica Limited develops clinic-ready, orally delivered live biotherapeutic products made from defined bacterial strains. Its target areas are immuno-oncology and inflammatory bowel disease. In March 2022 it raised GBP 51.18 million in Series B funding, with Flerie Invest and Tencent Investment co-leading and British Patient Capital and returning investors participating. Hans Rittinghausen is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in